1
|
Surdacki A, Bednarek J, Radziszewski W, Szczepkowski J, Dubiel JS, Ruskoaho H, Sedziwy L, Wieczorek E. Plasma ANP and cyclic GMP levels versus left ventricular performance at different AV delays in AV sequential pacing. Pacing Clin Electrophysiol 1994; 17:627-36. [PMID: 7516546 DOI: 10.1111/j.1540-8159.1994.tb02399.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Eleven resting patients with an implanted DDD pacemaker were studied. After 30 minutes of AV sequential pacing at a rate of 80 beats/min with three consecutive atrioventricular delays (AVDs; 100, 150, and 200 msec) peripheral venous blood was drawn for further analyses by specific radioimmunoassays of atrial natriuretic peptide (ANP) and the ANP second messenger, cyclic guanosine monophosphate (cGMP). Relative changes in left ventricular (LV) stroke volume following alterations of AVD were assessed by means of pulsed-Doppler echocardiography through measurement of LV outflow time-velocity integrals (TVI). The optimal AVD (oAVD) was defined in individual patients as that which was associated with the greatest TVI and with improvement over both other AVDs of more than 4%. The oAVD was found in nine patients. For these nine patients no significant differences in either plasma ANP or cGMP between various AVDs were observed. However, we found such differences with respect to values measured at oAVD; both ANP and cGMP levels were lowest at oAVD. Pooling together the data obtained in 11 patients at three AVDs, a positive correlation between ANP and cGMP levels was found (r = 0.7, P < 0.0001, n = 33). Moreover, changes of plasma ANP and cGMP induced by every AVD increment of 50 msec were also correlated (r = 0.6, P < 0.01, n = 22). It is concluded that in AV sequential pacing at rest plasma ANP reaches minimal levels at the AVD, which provides the best LV performance. Although levels of cGMP changed in parallel with those of ANP, low relative values of cGMP differences may limit the usefulness of cGMP assays in optimization of the AVD.
Collapse
Affiliation(s)
- A Surdacki
- Department of Cardiology, Jagiellonian University, Cracow, Poland
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Rodeheffer RJ, Naruse M, Atkinson JB, Naruse K, Burnett JC, Merrill WH, Frist WH, Demura H, Inagami T. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation 1993; 88:364-71. [PMID: 8339399 DOI: 10.1161/01.cir.88.2.364] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND Atrial natriuretic factor (ANF) is produced by myocardial tissue, and the plasma ANF concentration is known to be elevated in congestive heart failure (CHF). Data from animal models indicate that myocardial concentrations of ANF are depleted in CHF, and this has given rise to the hypothesis that CHF is characterized by depletion of stored ANF. To date, the molecular forms of ANF and their concentrations in atrial and ventricular myocardium remain poorly characterized in the normal and the failing human heart. METHODS AND RESULTS We measured ANF concentrations in fresh tissue from failing human hearts explanted at the time of cardiac transplantation and from organ donors whose normal hearts could not be used for transplantation. We determined total ANF and alpha, beta, and gamma ANF concentrations in the right and left atrial appendages, atrial free walls, and ventricles. In normal hearts, ANF concentration in the atrial appendages was 40-fold higher than ANF in the rest of the atrial free wall and in the ventricles. In the failing hearts, atrial appendage ANF concentrations increased 5- to 10-fold, and atrial free wall ANF concentrations increased 200-fold. Analysis of molecular forms of ANF demonstrated significant increases in the gamma and beta forms in the left atrial appendage of failing hearts. alpha, beta, and gamma ANF forms were also significantly increased in right and left atrial free wall tissue from failing hearts. In addition, failing hearts were characterized by absolute and relative increases in the precursor form gamma ANF. CONCLUSIONS These data from fresh tissues suggest that cardiac ANF stores are not decreased in severe CHF in humans; rather, chronic CHF is characterized by marked increases in atrial ANF tissue concentrations, particularly the beta and gamma ANF forms. These findings are consistent with intracellular accumulation of precursor ANF forms in severe chronic human CHF.
Collapse
Affiliation(s)
- R J Rodeheffer
- Department of Medicine, Mayo Clinic, Rochester, Minn 55905
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Radziszewski W, Surdacki A, Vuorinen P, Vapaatalo H, Saari M, Uusitalo A, Ruskoaho H, Dubiel JS, Gryglewski RJ. Plasma ANP and cyclic GMP after physical exercise in patients with mitral valve disease and in healthy subjects. Int J Cardiol 1993; 40:203-9. [PMID: 8225655 DOI: 10.1016/0167-5273(93)90002-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Plasma levels of both atrial natriuretic peptide (ANP) and cyclic GMP are elevated in patients with various heart diseases as compared to healthy subjects. In this study patients with advanced mitral valve disease (Group A) and healthy subjects (Group B) were exposed to symptom-limited upright stepwise physical exercise on a cycle ergometer. Concentrations of ANP and cyclic GMP were measured in plasma at rest (20 min in supine position) or 5 min after physical exercise by specific radioimmunoassays. Here we show that short dynamic exercise caused a significant increase in plasma levels of ANP and cyclic GMP, in both groups. In Group A strong correlation between plasma ANP and cyclic GMP was found at rest (r = 0.91, P < 0.001, n = 11) and after physical exercise (r = 0.85, P < 0.001, n = 11). In contrast, there was no correlation between plasma concentrations of ANP and cyclic GMP in Group B at rest (r = -0.16, P > 0.05, n = 10) or after exercise loading (r = 0.14, P > 0.05, n = 10). Absolute increases in circulating levels of both substances were not found to correlate in either group. These data suggest that exercise-induced elevations in plasma cyclic GMP may be due not only to ANP release but also to an as yet undetermined factor, possibly EDRF/NO.
Collapse
Affiliation(s)
- W Radziszewski
- Department of Pharmacology, Copernicus University School of Medicine, Cracow, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Abstract
Doxorubicin is an effective antineoplastic agent, but it frequently causes dose-related cardiotoxic effects. Because the atrial natriuretic peptide (ANP) level is elevated in children with heart defects, the authors measured the ANP levels in children to determine whether ANP might serve as a simple diagnostic indicator of cardiotoxic effects. Sixteen patients, 5 to 19 years of age, who were being treated with doxorubicin (45 mg/m2 body surface area) for various malignancies had ANP levels measured in plasma. There was a group of six children, with a significant peak of plasma ANP (pANP) levels 3 weeks after the administration of the drug. Of these six patients, five had received high cumulative doses of doxorubicin (160 to 370 mg/m2), and two of them went into congestive heart failure without a previous decline in left ventricular ejection fraction, a standard technique for monitoring cardiac function during treatment with doxorubicin. The other ten patients had normal ANP levels throughout the study, and signs of cardiac dysfunction did not develop. None of the patients in the control group who had cancer and were not treated with doxorubicin and none of the healthy volunteers had elevated ANP levels. These preliminary results suggest that pANP may be useful as an early and sensitive indicator for doxorubicin-related myocardial damage.
Collapse
Affiliation(s)
- M Bauch
- Department of Physiology, College of Medicine, University of Florida, Gainesville
| | | | | | | | | | | |
Collapse
|
5
|
Pucci A, Wharton J, Arbustini E, Grasso M, Diegoli M, Needleman P, Viganò M, Moscoso G, Polak JM. Localization of brain and atrial natriuretic peptide in human and porcine heart. Int J Cardiol 1992; 34:237-47. [PMID: 1532953 DOI: 10.1016/0167-5273(92)90020-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We have compared the localization of brain and atrial natriuretic peptide-like immunoreactivity in human and porcine hearts, using immunohistochemical techniques at both the light and ultrastructural level and specific antisera to amino-(cardiodilatin) and carboxy-terminal regions of the atrial natriuretic precursor molecule and to brain natriuretic peptide. Atrial myocardial cells in human fetal, normal adult and failing explanted hearts, displayed immunoreactivity for both brain and atrial natriuretic peptide-like sequences. At the subcellular level, brain natriuretic peptide-, cardiodilatin- and alpha-atrial natriuretic peptide-like immunoreactivity were co-localized to secretory granules in atrial myocardial cells. Immunoreactivity was also detected in the left (64%) and right ventricular free walls (23%) of 22 failing explanted hearts, but not in donor cardiac tissues. A gradient of natriuretic peptide immunostaining was observed across ventricular free walls and immunoreactivity for both natriuretic peptide sequences co-localized to secretory granules in a subpopulation of myocardial cells, concentrated in subendocardial regions of the ventricular walls. Brain and atrial natriuretic peptide-like immunoreactivity were also demonstrated in porcine atrial myocardium and cells of the ventricular conduction system. The parallel distribution of cardiac brain and atrial natriuretic peptide-like immunoreactivity suggests a dual regulation and co-storage of the natriuretic peptides in human and porcine hearts.
Collapse
Affiliation(s)
- A Pucci
- Department of Histochemistry, Royal Postgraduate Medical School, London, U.K
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Pucci A, Wharton J, Arbustini E, Grasso M, Diegoli M, Needleman P, Viganò M, Polak JM. Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity. J Pathol 1991; 165:235-41. [PMID: 1837051 DOI: 10.1002/path.1711650307] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Atrial amyloid deposits are common in the ageing human heart and contain alpha-atrial natriuretic peptide (proANP99-126) immunoreactivity. However, atrial myocytes secrete both amino and carboxy terminal fragments of the ANP prohormone (proANP1-126) and also express an homologous, but separate brain natriuretic peptide (BNP). Characteristic amyloid deposits were identified in the atria of 9/22 patients (26-63 years of age) with end-stage heart failure. Amyloid fibrils displayed immunoreactivity for both amino and carboxy terminal fragments of proANP1-126 and for the distinct BNP sequence. As in other endocrine organs, both mature and precursor peptide sequences appear to be constituents of amyloid fibrils. Whilst immunoreactivity for cardiac peptide hormones is co-localized in atrial amyloid deposits, it is uncertain whether the increase in natriuretic peptide expression which accompanies cardiac failure contributes to the incidence of isolated atrial amyloidosis.
Collapse
Affiliation(s)
- A Pucci
- Department of Histochemistry, Royal Postgraduate Medical School, London, U.K
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Glisson SN, Gutzke GE, Pifarre R, Rao TL. Atrial natriuretic peptide responses during anaesthesia in patients with refractory cardiomyopathies. Can J Anaesth 1991; 38:572-7. [PMID: 1834358 DOI: 10.1007/bf03008186] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
In patients with congestive heart failure, the release of atrial natriuretic peptide (ANP) is decreased. This study sought to determine the extent of ANP, sympathetic and haemodynamic responses to acutely increased atrial pressure in patients with cardiomyopathies undergoing orthotopic cardiac transplantation. Haemodynamic variables, plasma ANP, norepinephrine, and epinephrine concentrations were measured in 17 patients at five times before and after induction of anaesthesia using either ketamine 1.5 micrograms.kg-1 or sufentanil 3.6 +/- 0.3 micrograms.kg-1. Preinduction values in the ketamine and sufentanil groups were not significantly different. Compared with preinduction values, increases in mean arterial pressure (26%), pulmonary capillary wedge pressure (90%), right atrial pressure (107%), and heart rate (24%) occurred in the ketamine group while cardiac index decreased by 19% (P less than 0.05). Haemodynamic variables in the sufentanil group did not change at any of the times studied. Plasma concentrations of atrial natriuretic peptide were not different within or between treatment groups. Following tracheal intubation plasma norepinephrine levels increased by 116% in the ketamine group (P less than 0.05), but did not change in the sufentanil group. Plasma norepinephrine concentrations differed significantly between the ketamine and sufentanil groups. There were no differences in epinephrine concentrations in either group. Despite the anticipated haemodynamic and catecholamine differences found between the ketamine and sufentanil groups, the levels of plasma ANP were similar. Based upon these results, it is concluded that ANP exerts little influence in the control of fluid volume or blood pressure in patients with refractory cardiomyopathy.
Collapse
Affiliation(s)
- S N Glisson
- Department of Anesthesiology, Loyola University Chicago Medical Center, Maywood, Illinois 60153
| | | | | | | |
Collapse
|
8
|
Salvucci TJ, Roman C, Cha SD, Maranhao V. Atrial natriuretic peptide response to ionic and nonionic contrast left ventriculography. Clin Cardiol 1990; 13:644-8. [PMID: 2145110 DOI: 10.1002/clc.4960130911] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Atrial natriuretic peptide (ANP) levels were measured prior to and at 1 and 5 minutes postcontrast left ventriculography with an ionic contrast agent (diatrizoate), and a nonionic agent (iopamidol) and the results were compared. Since ionic contrast agents have been found to cause an increase in left ventricular end-diastolic pressure (LVEDP) and nonionic agents have been found to have less of an effect on LVEDP, we investigated the response of ANP levels, which have been found to increase secondary to increased LVEDP (atrial pressure), with both agents. A group of 38 patients who were scheduled for left heart catheterization for suspected coronary artery disease was included (19 in each group) and blood samples for ANP levels were drawn from the left ventricles. At the same time, heart rate, LVEDP, and left ventricular systolic pressure (LVSP) were also measured. It was found that the LVEDP increased significantly for both agents at 1 minute postventriculography, but no further change occurred at 5 min. Heart rate increased significantly in the diatrizoate group at 1 minute with a return of heart rate to preventriculography levels at 5 min, while the ANP level and LVSP remained unchanged at 1 minute postventriculography with both agents but increased significantly at 5 min in the diatrizoate group only. This difference in ANP response is not correlated with the LVEDP. The response of ANP may be related to heart rate and/or LVSP.
Collapse
Affiliation(s)
- T J Salvucci
- Department of Cardiology, Deborah Heart and Lung Center, Browns Mills, New Jersey 08015
| | | | | | | |
Collapse
|
9
|
Matsubara H, Mori Y, Takashima H, Inada M. Simultaneous measurement of alpha-human atrial natriuretic factor (hANF) and NH2-terminal fragment of pro-hANF in essential hypertension. Am Heart J 1989; 118:494-9. [PMID: 2528276 DOI: 10.1016/0002-8703(89)90263-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A radioimmunoassay specific for the N-terminal fragment of prohuman atrial natriuretic factor (hANF) was established with the use of antiserum for pro-hANF (1-30). Plasma levels of alpha-hANF-like immunoreactivity (LI) and pro-hANF (1-30)-Ll in patients with severe hypertension who were receiving a normal sodium diet were 56 +/- 5 pg/ml and 2710 +/- 118 pg/ml, respectively; these levels were significantly higher than control values. Levels of these peptides in patients with mild hypertension were similar to those of control subjects. Mean blood pressure correlated closely with alpha-hANF-Ll levels (r = 0.56, p less than 0.001) and pro-hANF (1-30)-Ll levels (r = 0.66, p less than 0.001) in patients receiving a normal sodium diet. Plasma alpha-hANF-Ll and pro-hANF (1-30)-Ll levels were significantly decreased 3 days in mild hypertension and 7 days in severe hypertension after initiation of a low-sodium diet with a decrease in blood pressure as compared to the initial values. These results suggest that plasma N-terminal fragment levels are elevated in proportion to the degree of hypertension, and they can be reduced by means of effective antihypertensive treatment.
Collapse
Affiliation(s)
- H Matsubara
- Department of Medicine, Kansai Medical University, Osaka, Japan
| | | | | | | |
Collapse
|
10
|
Abstract
This report has reviewed some of the cardiovascular aspects of ANP. The emergence of the heart as an endocrine organ requires that numerous questions be asked with regard to the importance of ANP to anesthesia and surgery. It is clear that the interaction of the hormone with other vasoactive compounds, including anesthetic agents, requires further elucidation. The accumulation of more information regarding the regulation of ANP and its cardiovascular setting will define its role in hemodynamic homeostasis in the acute clinical setting. Questions of specific interest to the anesthesiologist that require elucidation are: (1) Does the presence of abnormal ANP levels, associated with specific disease states, affect perioperative cardiovascular function? (2) Do cardiac surgery and CPB affect ANP-adrenergic interaction? (3) What is the relationship among blood volume, blood pressure, cation metabolism, and the ANP-renin-angiotensin system in perioperative patients? (4) What is the role of ANP as a therapeutic modality in surgical patients?
Collapse
Affiliation(s)
- R W McIntyre
- Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710
| | | |
Collapse
|
11
|
Manipulation of stretch-induced atriopeptin prohormone release and processing in the perfused rat heart. Proc Natl Acad Sci U S A 1988; 85:8365-9. [PMID: 2973064 PMCID: PMC282436 DOI: 10.1073/pnas.85.21.8365] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Atriopeptin (AP) is stored as the prohormone AP-126 [atrial natriuretic factor-(1-26)] in atrial granules. Cultured atrial myocytes synthesize and release only prohormone into the medium. HPLC analysis of the coronary venous effluent of media from perfused rat hearts subjected to right atrial stretch indicated the presence of the C-terminal mature hormone AP-28 [atrial natriuretic factor-(99-126)] and little or no prohormone. Absence of calcium from the perfusion medium increased total AP release and surprisingly blocked the proteolytic cleavage of the prohormone. Similarly, addition of the proteolytic inhibitor aprotinin to the perfusion medium suppressed the processing of the endogenous AP-126 released by atrial stretch. Aprotinin would be restricted to the extracellular space, which is therefore implicated as the site of prohormone processing. This suggestion was validated by the demonstration that the perfused rat heart could readily cleave exogenous prohormone to mature hormone, a process blocked by aprotinin. Hypothetically, the stimulus-release-processing event initiated by atrial stretch may require the concerted action of the synthetic cell (i.e., atrial myocyte) and a processing cell or site (e.g., the adjacent atrial mesenchymal cell) for the production of the mature AP-28, which is the circulating molecular form of this endocrine system.
Collapse
|